Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
123.29
+4.16 (3.49%)
At close: Nov 20, 2024, 4:00 PM
124.01
+0.72 (0.58%)
Pre-market: Nov 21, 2024, 4:13 AM EST
Neurocrine Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 2,243 | 1,887 | 1,489 | 1,134 | 1,046 | 788.1 | Upgrade
|
| Revenue Growth (YoY) | 25.72% | 26.76% | 31.34% | 8.38% | 32.71% | 74.67% | Upgrade
|
| Cost of Revenue | 716.2 | 604.7 | 487 | 342.4 | 285.1 | 207.4 | Upgrade
|
| Gross Profit | 1,527 | 1,282 | 1,002 | 791.1 | 760.8 | 580.7 | Upgrade
|
| Selling, General & Admin | 924.3 | 887.6 | 752.7 | 583.3 | 433.3 | 354.1 | Upgrade
|
| Operating Expenses | 924.3 | 887.6 | 752.7 | 583.3 | 433.3 | 354.1 | Upgrade
|
| Operating Income | 602.3 | 394.8 | 249 | 207.8 | 327.5 | 226.6 | Upgrade
|
| Interest Expense | -4.6 | -4.6 | -7.1 | -25.8 | -32.8 | -32 | Upgrade
|
| Interest & Investment Income | 92 | 57.4 | 11.2 | 3.8 | 12.6 | 19.2 | Upgrade
|
| EBT Excluding Unusual Items | 689.7 | 447.6 | 253.1 | 185.8 | 307.3 | 213.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | -6.2 | 28.4 | 30.8 | 20.9 | -17.7 | -13 | Upgrade
|
| Other Unusual Items | -138.4 | - | -70 | - | -18.4 | - | Upgrade
|
| Pretax Income | 521.6 | 332.1 | 213.9 | 101.4 | 106.7 | 46.5 | Upgrade
|
| Income Tax Expense | 135.7 | 82.4 | 59.4 | 11.8 | -300.6 | 9.5 | Upgrade
|
| Net Income | 385.9 | 249.7 | 154.5 | 89.6 | 407.3 | 37 | Upgrade
|
| Net Income to Common | 385.9 | 249.7 | 154.5 | 89.6 | 407.3 | 37 | Upgrade
|
| Net Income Growth | 102.04% | 61.62% | 72.43% | -78.00% | 1000.81% | 75.36% | Upgrade
|
| Shares Outstanding (Basic) | 100 | 98 | 96 | 95 | 93 | 92 | Upgrade
|
| Shares Outstanding (Diluted) | 104 | 101 | 99 | 98 | 98 | 96 | Upgrade
|
| Shares Change (YoY) | 2.91% | 2.12% | 1.02% | 0.10% | 2.19% | 0.31% | Upgrade
|
| EPS (Basic) | 3.86 | 2.56 | 1.61 | 0.95 | 4.37 | 0.40 | Upgrade
|
| EPS (Diluted) | 3.73 | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | Upgrade
|
| EPS Growth | 97.40% | 58.33% | 69.57% | -77.88% | 966.67% | 77.27% | Upgrade
|
| Free Cash Flow | 440.1 | 361.6 | 322.9 | 233.1 | 217.6 | 132.3 | Upgrade
|
| Free Cash Flow Per Share | 4.25 | 3.58 | 3.26 | 2.38 | 2.22 | 1.38 | Upgrade
|
| Gross Margin | 68.07% | 67.96% | 67.29% | 69.79% | 72.74% | 73.68% | Upgrade
|
| Operating Margin | 26.85% | 20.92% | 16.73% | 18.33% | 31.31% | 28.75% | Upgrade
|
| Profit Margin | 17.21% | 13.23% | 10.38% | 7.90% | 38.94% | 4.69% | Upgrade
|
| Free Cash Flow Margin | 19.62% | 19.16% | 21.69% | 20.56% | 20.81% | 16.79% | Upgrade
|
| EBITDA | 628 | 416.1 | 264.6 | 218.7 | 336.1 | 234 | Upgrade
|
| EBITDA Margin | 28.00% | 22.05% | 17.77% | 19.29% | 32.13% | 29.69% | Upgrade
|
| D&A For EBITDA | 25.7 | 21.3 | 15.6 | 10.9 | 8.6 | 7.4 | Upgrade
|
| EBIT | 602.3 | 394.8 | 249 | 207.8 | 327.5 | 226.6 | Upgrade
|
| EBIT Margin | 26.85% | 20.92% | 16.73% | 18.33% | 31.31% | 28.75% | Upgrade
|
| Effective Tax Rate | 26.02% | 24.81% | 27.77% | 11.64% | - | 20.43% | Upgrade
|
| Revenue as Reported | 2,243 | 1,887 | 1,489 | 1,134 | 1,046 | 788.1 | Upgrade
|
| Advertising Expenses | - | 159.9 | 149.7 | 139.8 | 64.8 | 40.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.